Smart Assistans AB has been acquired by Förenade Care AB
The private shareholders of Smart Assistans AB have sold the company to Förenade Care AB for an undisclosed consideration.
Smart Assistans provides personal care services for disabled adults, in compliance with the Swedish Act concerning Support and Services for Persons with Certain Functional Impairments. The company's services include assistance in practical tasks, as well as the promotion of patient well-being through joint social activities in various forms.
Based in Sweden, Förenade Care provides care and support services for people with disabilities. The company offers health care, social care and medical care services, in addition to operating care homes in Sweden. Förenade Care is part of Danish Förenade Group, a leading privately owned service company in the Nordic region, with approximately 8,000 employees.
Oaklins' team in Sweden advised the seller in this transaction.
Prata med transaktionsteamet
Relaterade transaktioner
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer